Evaluation of a commercially-available block for spatially fractionated radiation therapy

被引:41
|
作者
Buckey, Courtney [1 ,2 ]
Stathakis, Sotirios [1 ,2 ]
Cashon, Ken [3 ]
Gutierrez, Alonso [1 ,2 ]
Esquivel, Carlos [1 ,2 ]
Shi, Chengyu [1 ,2 ]
Papanikolaou, Nikos [1 ,2 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
[3] Dot Decimal Inc, Sanford, FL 32771 USA
来源
关键词
spatially fractionated radiotherapy; GRID therapy; compensators; CANCER;
D O I
10.1120/jacmp.v11i3.3163
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In this paper, we present the dosimetric characteristics of a commercially-produced universal GRID block for spatially fractioned radiation therapy. The dosimetric properties of the GRID block were evaluated. Ionization chamber and film measurements using both Kodak EDR2 and Gafchromic EBT film were performed in a solid water phantom to determine the relative output of the GRID block as well as its spatial dosimetric characteristics. The surface dose under the block and at the openings was measured using ultra thin TLDs. After introducing the GRID block into the treatment planning system, a treatment plan was created using the GRID block and also by creating a GRID pattern using the multi-leaf collimator. The percent depth doses measured with film showed that there is a shift of the dmax towards shallower depths for both energies (6 MV and 18 MV) under investigation. It was observed that the skin dose at the GRID openings was higher than the corresponding open field by a factor as high as 50% for both photon energies. The profiles showed the transmission under the block was in the order of 15-20% for 6 MV and 30% for 18 MV. The MUs calculated for a real patient using the block were about 80% less than the corresponding MUs for the same plan using the multileaf collimator to define the GRID. Based on this investigation, this brass GRID compensator is a viable alternative to other solid compensators or MLC-based fields currently in use. Its ease of creation and use give it decided advantages. Its ability to be created once and used for multiple patients (by varying the collimation of the linear accelerator jaws) makes it attractive from a cost perspective. We believe this compensator can be put to clinical use, and will allow more centers to offer GRID therapy to their patients.
引用
收藏
页码:2 / 11
页数:10
相关论文
共 50 条
  • [31] Performance of commercially-available cholesterol self-tests
    Kurstjens, Steef
    Gemen, Eugenie
    Walk, Selina
    Njo, Tjin
    Krabbe, Johannes
    Gijzen, Karlijn
    Elisen, Marc G. L. M.
    Kusters, Ron
    ANNALS OF CLINICAL BIOCHEMISTRY, 2021, 58 (04) : 289 - 296
  • [32] In-Vitro Evaluation of 52 Commercially-Available Essential Oils Against Leishmania amazonensis
    Monzote, Lianet
    Herrera, Isabel
    Satyal, Prabodh
    Setzer, William N.
    MOLECULES, 2019, 24 (07)
  • [33] Clinical aspects of spatially fractionated radiation therapy treatments
    Grams, Michael P.
    Deufel, Christopher L.
    Kavanaugh, James A.
    Corbin, Kimberly S.
    Ahmed, Safia K.
    Haddock, Michael G.
    Lester, Scott C.
    Ma, Daniel J.
    Petersen, Ivy A.
    Finley, Randi R.
    Lang, Karen G.
    Spreiter, Sheri S.
    Park, Sean S.
    Owen, Dawn
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2023, 111
  • [34] Spatially fractionated radiation therapy: History, present and the future
    Yan, Weisi
    Khan, Mohammad K.
    Wu, Xiaodong
    Simone, Charles B., II
    Fan, Jiajin
    Gressen, Eric
    Zhang, Xin
    Limoli, Charles L.
    Bahig, Houda
    Tubin, Slavisa
    Mourad, Waleed F.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2020, 20 : 30 - 38
  • [35] Combining FLASH and spatially-fractionated radiation therapy
    Prezado, Yolanda
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S28 - S29
  • [36] Validity and Reliability of a Commercially-Available Velocity and Power Testing Device
    Askow, Andrew T.
    Stone, Jason D.
    Arndts, Daniel J.
    King, Adam C.
    Goto, Shiho
    Hannon, Joseph P.
    Garrison, J. Craig
    Bothwell, James M.
    Esposito, Phil E.
    Jagim, Andrew R.
    Jones, Margaret T.
    Jennings, Will
    Oliver, Jonathan M.
    SPORTS, 2018, 6 (04):
  • [37] Summary of: The fluoride contents of commercially-available soya milks in the UK
    Paul Ashley
    British Dental Journal, 2014, 217 : 186 - 187
  • [38] COMPARISON OF SIX COMMERCIALLY-AVAILABLE DNA POLYMERASES FOR DIRECT PCR
    Miura, Masashi
    Tanigawa, Chihiro
    Fujii, Yoshito
    Kaneko, Satoshi
    REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2013, 55 (06): : 401 - 406
  • [39] Phantom evaluation of a commercially available three modality image guided radiation therapy system
    Ploquin, Nicolas
    Rangel, Alejandra
    Dunscombe, Peter
    MEDICAL PHYSICS, 2008, 35 (12) : 5303 - 5311
  • [40] Assessing the level of evidence for the benefit of commercially-available "cell therapy" treatments in the US for ocular diseases
    Chen, Andrew
    Simhaee, Daniel
    Nirwan, Rajinder Singh
    Albini, Thomas A.
    Sridhar, Jayanth
    Flynn, Harry
    Kuriyan, Ajay E.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)